- FDA authorizes StemCells to conduct trial of product candidate in patients with age-related macular degeneration
- Bayer receives approval to begin expanded access program for investigational prostate cancer therapy
- FDA removes clinical hold on trial of Idenix's investigational HCV therapy
- Discovery Labs' aerosol drug delivery system approved
- Merck's Janumet XR approved for type 2 diabetes
- Private FFS MA plans may be linked with higher costs for beneficiaries, GAO report shows
- Pediatric subspecialty telephone consultations may be cost-saving for Medicaid, research reveals
- Use of mental health services greater in health plans with parity in cost sharing, data find
- Public opinions appear split on health care affordability, satisfaction, survey finds
- In Brief: California Supreme Court
UCB, Astellas agree to develop, commercialize certolizumab pegol for RA in Japan
What's This?
UCB SA and Astellas Pharma Inc. entered into an agreement to jointly develop and market certolizumab pegol for the treatment of rheumatoid arthritis (RA) in Japan. UCB's U.S. subsidiary, UCB Inc., markets certolizumab pegol in the United States under the brand name Cimzia as a treatment for RA and Crohn's disease. Under the terms of the agreement between UCB and Astellas, UCB will manufacture and supply the product, while Astellas will manage the distribution. Together, the two firms...
UCB SA and Astellas Pharma Inc. entered into an agreement to jointly develop and market certolizumab pegol for the treatment of rheumatoid arthritis (RA) in Japan.
UCB's U.S. subsidiary, UCB Inc., markets certolizumab pegol in the United States under the brand name Cimzia as a treatment for RA and Crohn's disease.
Under the terms of the agreement between UCB and Astellas, UCB will manufacture and supply the product, while Astellas will manage the distribution. Together, the two firms will co-develop and co-market the drug in Japan.
UCB will receive an initial cash payment from Astellas and is eligible for clinical, regulatory and commercial milestone payments.
Last month, UCB and Otsuka Pharmaceutical Co. Ltd. terminated their collaboration to co-develop and co-promote certolizumab pegol as an RA therapy in the Japanese market.
Isotechnika terminates voclosporin agreement with Iljin 
What's This?
Isotechnika Pharma Inc. exercised its right to terminate the development, distribution and license agreement it entered into with Iljin Life Science Co. Ltd. regarding voclosporin for transplant and autoimmune indications. As a result, Isotechnika regained the full rights to voclosporin in these indications in the United States and other...
UCB, Otsuka discontinue immunology collaboration, focus on development of CNS drugs in Japan
What's This?
UCB SA and Otsuka Pharmaceutical Co. Ltd. discontinued their immunology collaboration and will instead focus on developing drugs for central nervous system disorders in the Japanese market.Specifically, the firms ended their agreement to co-develop and...
GSK exercises option to license ChemoCentryx's investigational RA therapy
What's This?
GlaxoSmithKline Plc (GSK) exercised its option to obtain an exclusive license for further development and worldwide commercialization of ChemoCentryx Inc.'s investigational rheumatoid arthritis (RA) drug, CCX354.ChemoCentryx will receive an option exercise fee of $25 million and will be eligible for regulatory and sales milestone payments. Upon successful development and commercialization of CCX354,...
Isotechnika, Vifor Pharma sign license agreement for development, commercialization of voclosporin
What's This?
Isotechnika Pharma Inc. entered into a global development and commercialization license agreement with Vifor Pharma Ltd. As part of the agreement, Vifor was granted an exclusive license to Isotechnika's lead compound, voclosporin, for the treatment of lupus and all proteinuric nephrology indications. The license is applicable in the United States and other...
ACR 2007 Scientific Meeting
November 6-11, 2007 Boston, MA- Denosumab, certolizumab show promise as potential treatments in RA
- Etanercept provides sustained efficacy, improved patient-reported outcomes in AS
- Targeting the IL-6 cytokine pathway presents exciting opportunities in variety of disease states, experts report
- Adalimumab improves peripheral arthritis, enthesitis, axial signs, symptoms of AS in patients with long-standing disease treated in real-life practice, researchers report
- Tocilizumab improves function, QOL in patients with RA who respond inadequately to conventional DMARDs, researchers report
EULAR 2007 Annual Congress
June 13-16, 2007 Barcelona, Spain- Anti-TNF agents may slow, protect against RA-related joint destruction, disability, work loss
- Biologics represent useful treatment for PsA; other therapies, approaches require more study
- Certolizumab pegol improves signs, symptoms of RA among patients with insufficient response to methotrexate, study data show
- First-line anti-TNF agents yield high rate of long-term response, well tolerated in patients with AS, study demonstrates
- Patients with RA, PsA, AS who have not responded to etanercept, infliximab show response to adalimumab, according to subanalyses
- FDA accepts Pfizer's NDA for tofacitinib in RA for review
- Boehringer Ingelheim, AbGenomics terminate agreement to develop, commercialize therapeutic monoclonal antibody
- Anika Therapeutics licenses U.S. rights to Monovisc to DePuy Mitek
- Isotechnika, Vifor Pharma sign license agreement for development, commercialization of voclosporin
- GSK exercises option to license ChemoCentryx's investigational RA therapy
- UCB, Immunomedics restructure epratuzumab agreement
- UCB, Otsuka discontinue immunology collaboration, focus on development of CNS drugs in Japan
- Merck dissolves AD agreement with Acumen, signs PI3K inhibitor agreement with Exelixis
- GSK, Human Genome start late-stage trial to evaluate subcutaneous form of Benlysta in patients with lupus
- Medicare Part D coverage gap linked to discontinuation among patients taking certain osteoporosis drugs, findings demonstrate
